TickerGuard
Buy Day today: Neutral (55) Mixed market breadth · no major macro event
HCM

HUTCHMED DRC

Healthcare · Drug Manufacturers - Specialty & Generic

13.90$ +0.3% vs. previous close Closing price · As of: Sep 25, 2026

Ownership

Ownership Structure

Who owns HUTCHMED DRC (HCM)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 60.2% of the shares are freely tradable; institutional investors hold 2.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 2.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.01%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 60.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 0.2%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 174Mio.

Largest Shareholders

Institutions

Institutions HCM
Name Stake (%) Shares Change (%) Date
Schroder Investment Management Group 0.85 1,477,494 +0.0 06/30/2026
Allianz Asset Management AG 0.39 674,511 -19.5 06/30/2026
State Street Corp 0.18 304,829 -5.1 03/31/2026
AIA Group Ltd 0.17 291,229 +0.0 06/30/2026
M&G PLC 0.14 242,791 -5.0 06/30/2026
Amundi 0.13 232,246 +4.0 03/31/2026
Renaissance Technologies Corp 0.08 132,062 -2.1 03/31/2026
BNP Paribas Arbitrage, SA 0.06 106,504 +239.2 03/31/2026

Funds

Funds HCM
Name Stake (%) Shares Change (%) Date
Allianz Oriental Income P USD 0.24 420,025 -31.0 07/31/2026
M&G Global Emerging Markets GBP I Acc 0.11 190,854 -1.6 05/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?